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ABSTRACT
The strong ropy character of the Scandinavian fer-
mented milk viili is conferred by the exopolysaccharides
(EPS) produced by lactococcal strains. These biopoly-
mers can be responsible for some health benefits. We
have assessed the influence of the EPS fraction isolated
from commercial viili on the adhesion of some probiotics
and pathogens to human intestinal mucus. Concentra-
tions of viili EPS greater than 0.1 mg/mL promoted a
decrease in adherence of Bifidobacterium lactis Bb12
and Lactobacillus rhamnosus GG and this effect was
dose-dependent. However, no modifications were de-
tected on the adhesion levels of the pathogenic strains
tested at a concentration of 1 mg/mL of EPS. Results
obtained in the present work should be considered in
the design of new probiotic products.
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Exopolysaccharide (EPS)-producing lactic acid bacte-
ria are commonly used as starter cultures in the manu-
facture of yogurt, kefir, and some Scandinavian fer-
mented milks such as “la˚ngfil” in Sweden, or “viili” in
Finland (Duboc and Mollet, 2001). Viili is made with a
traditional mesophilic mixed-strain starter mainly com-
posed of Lactococcus lactis ssp. cremoris EPS-producing
strains that confer its strong ropy character (Saxelin
et al., 1986). The EPS from viili is a pentasaccharide
composed of galactose, glucose, and rhamnose in similar
ratios (2:2:1), and has an anionic nature due to the pres-
ence of a phosphate group. The physical properties of
this EPS in aqueous solutions (Tuinier et al., 1999; Hi-
gashimura et al., 2000) as well as its viscosity-intensi-
fying ability in fermented skimmedmilk (Ruas-Madiedo
et al., 2002) have been determined. In addition, it has
been suggested that this biopolymer could reduce the
blood cholesterol level of rats (Nakajima et al., 1992),
and that it has anticarcinogenic ability (Kitazawa et
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al., 1991) mediated by the stimulation of the mitogenic
activity of B lymphocytes (Kitazawa et al., 1992).
Probiotics have been defined as “viable microorgan-
isms that exhibit a beneficial effect on the health of the
host when they are ingested” (Salminen et al., 1998).
Strains of the genera Lactobacillus and Bifidobacterium
are the most common probiotics used for human con-
sumption; they can be present together with other lactic
acid bacterial starters in commercial dairy products
(Playne et al., 2003; Talwalkar andKailasapathy, 2004).
One of the main criteria for the selection of probiotics is
the ability to adhere to the intestinal mucosa allowing
a transitory colonization of the intestinal tract, which
could modify the adhesion of other microorganisms
(Dunne et al., 2001). Ouwehand and coworkers (2000)
have shown that the presence of Lactobacillus rhamno-
sus GG resulted in a 2-fold increase in the adherence of
Bifidobacterium lactis Bb12 to a human mucus model,
suggesting a synergistic effect. However, no studies are
currently available about the influence of EPS included
in commercial products on the adhesion of probiotics. In
the present work, we evaluated the adhesion properties
to human intestinalmucus of 2 common probiotics found
in themarket,Bifidobacteriumanimalis ssp. lactisBb12
and Lb. rhamnosus GG, as affected by the presence of
the EPS isolated from commercial fermented milk, viili.
The ability of this EPS to interfere with the adhesion of
several enteric pathogens was also investigated.
Three different batches of the commercial fermented
milk viili containing 1% fat were purchased from the
supermarket. For EPS isolation, TCA was added to ob-
tain afinal concentration of 12% (wt/wt), and themixture
was vigorously stirred for 1 h at room temperature. Mi-
croorganisms and precipitated milk proteins were re-
moved by centrifugation. Each EPS fraction was precipi-
tated with 2 volumes of absolute ethanol (4°C for 48
h), resuspended in ultrapure water, dialyzed (3 d, 4°C,
molecularweight cut off: 12 to 14 kDa), and finally lyoph-
ilized. For the adhesion experiments, the viili EPS frac-
tions were resuspended at different concentrations (0.1,
0.5, and 1.0 mg/mL) in HEPES-Hanks’ buffer (HH), pH
7.4 (10 mM HEPES). The polymer yield of the EPS-
viili was determined by gel permeation chromatography.
Exopolysaccharide fractions (100 L) were analyzed in a
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TSK-GEL G5000PWXL (Supelco/Sigma-Aldrich Quı´mica
S.A., Madrid, Spain) column protected with a TSK-GEL
PW guard column (Supelco). The EPS was isocratically
separated at a flow rate of 0.6 mL/min at 40°C using 0.1
M NaNO3 as the mobile phase. A PDA 996 detector
(Waters, Milford, MA) was used to check the absence of
protein in the elution peak corresponding to the EPS
and a 410Refractometer (Waters)was used for the quan-
tification of the polymer. The EPS concentration (mg/
mL) andmolar mass (Da) were obtained using the linear
regression equations (R2 ≥ 0.994 and R2 ≥ 0.999, respec-
tively) calculated from different molar mass standards
of dextran. Finally, the protein content of the viili EPS
fraction was measured using the bicinchoninic acid
(BCA) protein assay kit (Pierce, Rockford, IL), following
the manufacturer’s instructions.
A human intestinal mucus model (Ouwehand et al.,
2002) was used to assess the effect of the EPS in the
adhesion of the probiotics Lb. rhamnosus GG and B.
animalis ssp. lactis Bb12 and the pathogens Listeria
monocytogenes ATCC 15313, Clostridium difficile ATCC
9689, Enterobacter sakazakii ATCC 29544, Salmonella
enterica biovar. Typhimurium ATCC 29631, and Esche-
richia coli NCTC 8603. Probiotics were grown overnight
in MRS-cysteine (at 37°C in anaerobic conditions) and
pathogenswere grown inGifu anaerobicmedium (Nissui
Pharmaceuticals, Tokyo, Japan) broth at 37°C in the
presence of 10 Ci/mL of tritiated thymidine (5-3H-thy-
midine, specific activity: 120 Ci/ mmol; Amersham Bio-
science, Buckinghamshire, UK). Standardized (optical
density at 600 nm: 0.25 ± 0.01) cell suspensions were
prepared in HH buffer without and with different con-
centrations of the EPS from viili, and bacterial adhesion
was determined according to Kirjavainen and coworkers
(1998). In short, 100L of intestinal mucuswas immobi-
lized on polystyrene microtiter plate wells by overnight
incubation at 4°C. After washing twice with HH buffer,
wells were filled with 100 L of the standardized bacte-
rial suspensions, and incubated for 1 h at 37°C. After-
wards, the unattached bacteria were removed by wash-
ing twice with HH buffer, and the adhering cells were
released and lysed with 200 L of lysis solution [1% (wt/
vol) SDS in 0.1 M NaOH] at 60°C for 1 h. The content
of wells was transferred to microfuge tubes containing
scintillation liquid (OptiPhase HiSafe 3, Wallac Oy,
Turku, Finland), and the radioactivity of lysed bacteria
was determinedwith a liquid scintillation counter. Adhe-
sion results were expressed as the percentage of radioac-
tivity recovered after adhesion relative to the radioactiv-
ity of the bacterial suspension initially added to the im-
mobilized mucus. Experiments were carried out at least
in triplicate and 1-way ANOVA was performed to deter-
mine the effect of EPS concentration on the adhesion of
strains tested.
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Table 1. Lactococcal counts, pH values, and exopolysaccharides




Lactococcal counts (log cfu/mL) 8.07 ± 0.25
pH 4.35 ± 0.03
EPS yield (mg/kg of viili) 71.45 ± 9.91
EPS fraction1
Protein content (% wt/wt) 3.67 ± 1.09
EPS content (% wt/wt) 79.80 ± 15.31
Molar mass (×106 Da) 10.41 ± 2.12
1Protein and EPS content of the viili EPS fraction were obtained
after the purification procedure; molar mass represents the average
molar mass of the purified EPS.
The lactococcal counts, pH, and EPS yield of the 3
batches of viili analyzed are shown in Table 1. The pH
values of viili were around 4.35 and the bacterial counts
on M17 agar ranged from 7.82 to 8.32 log cfu/mL. The
EPS yield measured by gel permeation chromatography
was around 71 mg/kg of viili. No previous data were
available in literature concerning the EPS yield from
commercial viili. However, our results were similar to
that obtained in skimmed milks fermented with several
viili lactococcal strains, inwhich yields of single indepen-
dent cultures varied from 40 to 80 mg/L as measured
by gel permeation chromatography (Ruas-Madiedo et al.,
2002). Higher EPS yields (from 164 to 263 mg/L) were
obtained by a colorimetric method with other lactococcal
strains growing in skimmed milk (Yang et al., 1999). In
addition to the type of strains used for fermentation,
differences inmilk composition, incubation temperature,
EPS isolation procedure, and EPS quantification meth-
ods could account for the variability in the EPS yield
reported by different authors (Ruas-Madiedo and de los
Reyes-Gavila´n, 2005). Polysaccharide was the major
component of the EPS fraction, comprising around 80%
(wt/wt), and the protein content was lower than 4% (wt/
wt; Table 1). The average molar mass of the EPS viili
was around 10 × 106 Da (Table 1), distributed in a single
nonuniform peak. The reported size of the EPS produced
by several viili lactococcal strains is lower, ranging be-
tween 2.5 × 104 and 1.4 × 106 Da (Ruas-Madiedo and de
los Reyes-Gavila´n, 2005). The considerable width of our
peak ofEPS fromviili pointed to thepresence of polymers
of different sizes. Probably, the aggregation between
some EPS molecules would account for the high molar
mass values detected in our case.
Figure 1 shows the adhesion levels to human intesti-
nal mucus of the commercial probiotic strains Lb. rham-
nosus GG and B. animalis ssp. lactis Bb12. In the ab-
sence of the polymer, the probiotic strains showed good
adherence to human intestinalmucuswith levels compa-
rable to those previously reported (Ouwehand et al.,
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Figure 1. Adhesion to human intestinal mucus of the probiotics strains Lactobacillus rhamnosus GG and Bifodobacterium animalis ssp.
lactis Bb12 in the presence of increasing concentrations (0, 0.1, 0.5, and 1 mg/mL) of the exopolysaccharide (EPS) fraction isolated from the
commercial fermented milk, viili. Bars with different superscript letters within each plot are significantly different (P < 0.05).
2000; Gueimonde et al., 2005). However, the adherence
of both strains significantly decreased (P < 0.001) when
the EPS was present at concentrations higher than 0.1
mg/mL, with the effect being dose-dependent. This con-
centration is close to that found in the commercial viili
(0.071 mg/mL) analyzed in the present work. The mini-
mum adhesion was obtained at EPS concentrations of 1
mg/mL, at which a decrease of 2-fold and 1.7-fold with
respect to the control (without EPS) was detected for Lb.
rhamnosus GG and B. lactis Bb12, respectively. These
Figure 2. Adhesion to human intestinal mucus of several enteric pathogens in the presence of increasing concentrations (0, 0.1, 0.5, and
1 mg/mL) of the exopolysaccharide (EPS) fraction isolated from the commercial fermented milk, viili.
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results indicated that the EPS villi fraction could com-
petitively inhibit adhesion to human intestinal mucus
of the commercial probiotics tested.
The effect of EPS from viili on the adhesion of 5 patho-
gens to mucus is shown in Figure 2. In general, the
adhesion level of the pathogens analyzed was lower than
that of the probiotic bacteria. The En. sakazakii and E.
coli strains displayed the highest adhesion levels (be-
tween 6 and 8%), whereas S. enterica biovar. Typhimu-
rium and C. difficile showed values around 3%. The low-
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est level of adhesion was found with L. monocytogenes
with values around 1%, which indicates a very poor ad-
herence capability. The results obtained were slightly
lower than those recently reported for the samemicroor-
ganisms (Collado et al., 2005), and could be due to the
different origin of human mucus used in each case. Con-
trary to the results obtained for probiotic strains, no
significant differences (P > 0.05) attributable to the pres-
ence of the EPS fraction were detected on the adhesion
of the 5 pathogenic strains tested.
In this study, we have shown that the EPS fraction
isolated from the commercial fermented milk, viili,
caused a decrease in the adhesion of the commercial
probiotic strains Lb. rhamnosus GG and B. animalis
ssp. lactis Bb12 without modifying adherence of some
pathogens to human intestinal mucus. This could indi-
cate that factors involved in the adhesion of probiotics
and pathogens to mucus could be different. It also seems
that the effect of EPS on adhesion is dependent on the
strain tested. Our preliminary results suggest that the
EPS fromviili could compete in vitro for similar adhesion
targets on themucus aswell as probiotic strains or that it
could attach to the cellular surface of probiotics. Further
studies on the effect of EPS from lactic bacteria on bacte-
rial adhesion are needed to establish a mechanism of
action. On the other hand, the effect of EPS against the
adhesion of probiotic bacteria was detected in doses of
EPS (0.1 mg/mL) close to that found in the commercial
fermented milk. Thereby, the possible effect of EPS pro-
duced by the Lc. lactis ssp. cremoris strains included in
fermented milks on the adhesion to intestinal mucus of
probiotics should be considered in the design of new
probiotic products.
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